background
nasal
potenti
differ
npd
intestin
current
measur
icm
function
cftr
test
use
adjunct
diagnost
tool
cystic
fibrosi
cf
smoke
system
neg
impact
cftr
function
diagnost
comparison
npd
icm
impact
smoke
cftr
test
done
method
sweat
chlorid
test
npd
icm
perform
patient
cf
sweat
chlorid
mmoll
includ
pancreat
suffici
ps
patient
healthi
control
includ
smoker
npd
cftr
respons
clfree
isoproterenol
perfus
iso
compar
icm
cftr
respons
forskolinibmx
carbachol
histamin
sc
forskolinibmx
carbacholhistamin
result
mean
npd
cftr
respons
icm
cftr
respons
patient
cf
healthi
control
significantli
differ
p
patient
cf
ps
pancreat
insuffici
pi
smoker
decreas
cftr
respons
measur
npd
p
icm
trend
toward
decreas
cftr
respons
ns
three
healthi
control
smoker
npd
respons
within
cfrang
contrast
npd
overlap
icm
respons
patient
cf
control
conclus
icm
superior
npd
distinguish
patient
cf
sweat
chlorid
mmoll
healthi
control
includ
smoker
neither
npd
icm
differenti
patient
cf
ps
pi
smoke
neg
impact
cftr
function
healthi
control
measur
npd
challeng
diagnost
interpret
npd
icm
cystic
fibrosi
cf
diagnos
base
defin
clinic
phenotyp
confirm
cystic
fibrosi
transmembran
regul
cftr
dysfunct
commonli
demonstr
sweat
chlorid
valu
mmoll
andor
detect
two
cfcaus
mutat
small
increas
number
patient
present
clinic
symptom
characterist
cf
intermedi
mmoll
neg
mmll
sweat
test
less
two
cfcaus
mutat
queri
cf
patient
specif
sensit
cftr
function
test
exclud
confirm
cftr
function
defect
characterist
cf
need
cftr
modul
correct
drug
improv
cftrfunction
cell
cultur
test
effect
cfpatient
especi
rare
mutat
cftrfunction
test
low
variabl
high
reproduc
need
addit
sweat
test
two
addit
cftr
function
test
develop
past
year
nasal
potenti
differ
npd
measur
intestin
current
measur
icm
cftr
function
measur
vivo
respiratori
epithelium
npd
ex
vivo
superfici
rectal
biopsi
icm
intern
standard
oper
procedur
sop
establish
test
test
block
epitheli
sodium
channel
amilorid
stimul
campmedi
cftrmediat
chlorid
transport
chloridefre
solut
isoproterenol
npd
forskolin
ibmx
icm
addit
cholinerg
chlorid
transport
test
carbachol
icm
chang
chloridefre
isoproterenol
perfus
iso
npd
sum
respons
carbachol
forskolinibmx
plu
histamin
sc
forskolinibmx
carbacholhistamin
icm
propos
best
paramet
cftr
function
techniqu
discrimin
cf
patient
healthi
control
npd
icm
compar
clinic
trial
lack
smoke
system
neg
impact
cftrfunction
impact
diagnost
aspect
npd
icm
investig
perform
npd
icm
measur
cfpatient
healthi
control
determin
abil
measur
differenti
cf
patient
healthi
control
influenc
smoke
cftr
function
healthi
control
octob
februari
patient
cf
healthi
control
recruit
justusliebigunivers
giessen
germani
studi
diagnosi
cf
base
least
one
clinic
manifest
cf
sweat
chlorid
mmoll
presenc
two
cfcaus
mutat
pancreat
suffici
ps
defin
fecal
elastas
stool
healthi
control
clinic
manifest
cf
sweat
chlorid
valu
mmoll
noncf
smoke
defin
activ
passiv
exposur
tobacco
smoke
exclus
criteria
particip
anoth
medic
clinic
trial
past
day
acut
respiratori
symptom
intak
ivacaftor
known
hemorrhoid
bleed
diathesi
ethic
committe
giessen
approv
protocol
studi
perform
accord
declar
helsinki
written
inform
consent
obtain
particip
age
year
older
particip
younger
year
age
written
inform
consent
obtain
particip
parent
legal
guardian
ageappropri
consent
obtain
particip
sweat
test
npd
icm
perform
day
subject
sweat
test
perform
accord
clinic
laboratori
standard
institut
guidelin
sweat
stimul
collect
system
wescor
data
shown
ratio
mean
standard
deviat
incl
median
minmax
p
cfall
versu
control
p
cfpi
versu
cfp
inc
logan
usa
use
chlorid
measur
chlorid
titrat
sweat
chlorid
level
mmoll
interpret
within
cf
rang
mmoll
equivoc
mmol
normal
npd
perform
one
oper
accredit
cystic
fibrosi
foundat
cff
therapeut
develop
network
tdn
follow
cff
tdn
sop
version
januari
use
terbutalin
substitut
isoproterenol
accord
sop
chloridefre
isoproterenol
respons
iso
npd
cftr
respons
wilschanksi
score
defin
e
respons
chloridefre
isoproterenolrespons
amilorid
repres
cftr
respons
calcul
averag
best
result
nostril
iso
interpret
normal
mv
cf
rang
mv
equivoc
result
mv
wilschanski
score
interpret
normal
cfrang
equivoc
mean
iso
mv
healthi
control
npd
repeat
differ
day
measur
highest
iso
report
measur
confirm
iso
cf
rang
cftr
genotyp
sequenc
multiplex
ligationdepend
probe
amplif
offer
part
particip
clinic
care
report
part
baselin
data
genotyp
healthi
control
ethic
approv
icm
least
superfici
rectal
biopsi
obtain
suction
biopsi
aspir
biopsi
instrument
accord
wilit
ulrich
gmbh
ulm
germani
without
prior
bowel
prepar
biopsi
immedi
store
icecold
buffer
solut
dulbecco
phosphat
buffer
salin
indomethacin
final
concentr
mount
adequ
tissu
slider
mount
slider
heat
slightli
sparg
co
system
basal
resist
measur
appli
short
current
puls
regist
correspond
chang
v
typic
rang
ohm
cm
vcc
multichannel
voltag
current
clamp
physiolog
instrument
san
diego
usa
voltag
clamp
mv
raw
short
circuit
current
r
sc
record
due
differ
slider
differ
area
mm
diamet
apertur
slider
area
cm
mm
diamet
apertur
slider
area
cm
physiolog
instrument
san
diego
usa
raw
r
sc
convert
sc
cm
appli
carbachol
stimul
cholinerg
cl
secret
open
basolater
k
channel
seros
compart
sc
respons
evok
qualiti
control
biopsi
equilibr
meyler
buffer
basal
sc
note
amilorid
block
amiloridesensit
sodium
channel
ad
mucos
compart
min
sc
stabl
forskolin
ibmx
stimul
campdepend
cftrcl
transport
ad
mucos
seros
compart
sc
forskolinibmx
minimum
min
genistein
cftrpotenti
ad
compart
minimum
min
carbachol
ad
seros
compart
sc
carbachol
minimum
min
acid
did
block
noncftrcl
channel
ad
mucos
compart
min
histamin
stimul
ca
proteinkinas
cmediat
cftr
cl
secret
ad
seros
compart
sc
histamin
open
circuit
final
transepitheli
voltag
final
resist
measur
appli
short
current
puls
begin
preliminari
data
suggest
averag
sc
forskolinibmx
carbacholhistamin
best
diagnost
icm
paramet
chlorid
secretori
respons
icm
cftr
respons
refer
rang
establish
data
present
mean
standard
deviat
sd
normal
distribut
variabl
respect
median
valu
percentil
nonnorm
distribut
variabl
group
comparison
perform
use
student
test
mannwhitney
u
test
normal
nonnorm
distribut
variabl
respect
statist
signific
defin
p
analys
perform
ibm
spss
statist
releas
ibm
armonk
usa
studi
includ
patient
cf
healthi
control
median
age
year
respect
ns
tabl
consequ
inclus
criteria
sweat
chlorid
valu
distinguish
patient
cf
healthi
control
p
although
mean
sweat
chlorid
differ
cfp
cfpi
patient
p
individu
overlap
occur
tabl
figur
mean
npd
cftr
respons
significantli
discrimin
cf
patient
healthi
control
p
patient
cf
ps
versu
pi
tabl
four
healthi
control
averag
iso
mv
three
four
control
repeat
averag
npd
cftr
respons
cfrang
iso
mv
healthi
control
figur
two
addit
control
use
wilschanski
score
healthi
control
figur
healthi
control
smoker
cftr
genotyp
offer
three
healthi
control
part
clinic
routin
none
two
cfcaus
mutat
tabl
icm
median
rectal
biopsi
sampl
per
patient
without
sever
advers
event
mean
icm
cftr
respons
significantli
differ
cf
patient
healthi
control
p
patient
cf
ps
versu
pi
tabl
could
detect
agedepend
respons
isoproterenolforskolin
contrast
npd
overlap
cfpatient
control
figur
use
best
instead
averag
npd
cftr
respons
overlap
chang
addit
file
use
best
instead
averag
icm
cftr
respons
result
one
overlap
addit
file
healthi
control
smoke
influenc
sweat
chlorid
ns
decreas
cftr
function
measur
npd
p
tabl
figur
figur
correl
averag
forskolinibmx
carbachol
histamin
icm
averag
iso
npd
normal
rang
shown
left
dot
line
intermedi
rang
shown
solid
dot
line
higher
forskolin
ibmx
carbachol
histamin
repres
better
cftr
respons
result
intermedi
even
abnorm
npd
result
icm
sweat
chlorid
result
trend
icm
measur
indic
smoke
might
affect
cftr
respiratori
tract
also
intestin
tabl
figur
icm
superior
npd
distinguish
cf
patient
sweat
chlorid
mmoll
healthi
control
includ
smoker
neither
npd
icm
diff
rentiat
patient
cf
ps
pi
smoke
neg
impact
cftr
function
healthi
control
measur
npd
challeng
diagnost
interpret
npd
trend
icm
indic
smoke
might
affect
cftr
respiratori
tract
also
intestin
impact
diagnost
interpret
npd
use
diagnost
test
cf
sinc
late
studi
shown
sensit
specif
iso
separ
pi
patient
cf
healthi
control
experi
broader
spectrum
patient
cf
equivoc
patient
sweat
chlorid
mmoll
less
two
cfcaus
mutat
describ
clinic
relev
overlap
iso
even
homozyg
patient
residu
cftr
npd
respons
without
observ
clinic
differ
describ
center
introduc
intermedi
categori
iso
interpret
highest
npd
cftr
respons
use
composit
score
includ
sodium
chlorid
conduct
irrespect
diagnost
criteria
result
show
clinic
relev
overlap
patient
cf
healthi
control
normal
averag
npd
cftr
respons
exclud
cf
abnorm
averag
npd
cftr
respons
could
occur
healthi
control
especi
smoker
lead
falseposit
diagnosi
cf
repeat
measur
patholog
npd
respons
reduc
falseposit
result
healthi
control
cohort
recommend
standard
approach
icm
develop
research
tool
cftr
function
use
diagnost
test
sinc
earli
two
differ
protocol
establish
freiburg
protocol
origin
adapt
rotterdam
protocol
use
newest
ecfsicmsop
adapt
rotterdam
protocol
combin
campmedi
cl
secret
carbachol
histamin
rotterdam
protocol
respons
separ
patient
cf
without
cf
patient
cf
ps
pi
accord
result
loss
cftr
protein
cf
heterozygot
could
detect
icm
independ
protocol
rotterdam
protocol
de
jong
postul
icm
respons
proport
cftr
amount
apic
membran
coloncyt
except
low
level
could
therefor
detect
loss
cftr
express
function
therefor
mild
mutat
could
result
falseneg
icm
interestingli
derich
report
patient
sweat
chlorid
mmoll
fewer
two
cfcaus
mutat
sequenc
normal
icm
respons
judg
cf
unlik
result
new
ecfsicm
sop
confirm
high
predict
valu
practic
adapt
icm
rotterdam
protocol
data
suggest
npd
like
detect
cftr
dysfunct
healthi
control
icm
sweat
test
could
explain
tissu
specif
differ
cftr
express
altern
chlorid
channel
express
extrins
factor
et
al
show
ident
cftr
express
respiratori
intestin
tract
patient
healthi
control
highli
variabl
cftr
express
nose
colon
homozyg
patient
describ
vari
therefor
respiratori
intestin
tract
individu
cftr
express
seem
relev
tissu
specif
express
altern
chlorid
channel
could
contribut
chlorid
conduct
describ
distal
colon
furthermor
previou
infect
milder
trauma
smoke
increas
paracellular
permeabl
decreas
cftr
express
cftr
respons
except
smoke
extrins
factor
relev
npd
rectal
biopsi
smoke
caus
decreas
npd
respons
although
decreas
system
cftr
function
mediat
acrolein
raju
et
al
demonstr
decreas
icm
cftr
respons
healthi
smoker
compar
nonsmok
result
confirm
find
contrast
npd
smoke
influenc
diagnost
cutoff
icm
cohort
therefor
icm
seem
robust
diagnost
test
npd
distinguish
primari
secondari
cftr
dysfunct
import
interpret
npd
adjunct
diagnost
test
patient
querycf
expos
smoke
limit
studi
includ
small
number
particip
group
lack
patient
cf
sweat
chlorid
valu
mmoll
patient
congenit
bilater
absenc
va
deferen
cbavd
strength
studi
genotyp
healthi
control
abnorm
cftr
npd
respons
use
standard
protocol
sweat
test
npd
icm
figur
averag
forskolinibmx
carbachol
histamin
icm
healthi
control
accord
smoke
statu
higher
forskolinibmx
carbachol
histamin
repres
better
cftr
respons
